111 Inc ADR Dossier
Qualitative Analysis
Business overview
111, Inc. (NASDAQ: YI) is a leading tech-enabled healthcare platform company in China. The company operates an integrated online and offline platform, digitally connecting patients with pharmaceutical products and healthcare services. It operates through two primary segments: B2B (wholesale) and B2C (retail). The B2B segment, powered by its '1 Drug Mall' platform, serves as a virtual pharmacy network and one-stop shop for offline pharmacies to source pharmaceutical products. The B2C segment, operating through '1 Pharmacy' (online retail drugstore) and '1 Clinic' (internet hospital), provides consumers with direct access to medications, online medical consultations, and electronic prescription services. Unlike competitors that rely heavily on parent-company traffic, 111, Inc. focuses on the B2B supply chain and digital tools for independent pharmacies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from a capital-intensive, self-operated fulfillment network to a warehouse partnership model. Under this model, divested fulfillment facilities join the ecosystem as partners, generating recurring commission income for 111, Inc. rather than bearing operational and capital burdens.
Expected impact: Sustained gross margin expansion, reduced fulfillment expenses, and structurally improved liquidity and profitability.
Enhancing supply chain capabilities and expanding the virtual pharmacy network. The initiative focuses on optimizing inventory value, increasing customer count, and systematically improving logistics through traceability code scanning, relay picking, and optimal carrier matching.
Expected impact: Improved operational efficiency, reduced total fulfillment costs, and a solid foundation for B2B marketplace growth.
Integrating AI-enabled capabilities across multiple operational scenarios, including demand forecasting, inventory optimization, fulfillment routing, and merchant operation management, alongside deploying AI agent-based solutions in pharmacies.
Expected impact: Enhanced operational efficiency, reduced technology costs, and transition from a transaction-driven distributor to an intelligent healthcare platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Securing general distribution rights for high-margin products (such as the anti-infection drug 'Cravit') targeting small and medium-sized chain pharmacies, which strengthens brand building and market penetration.
Terms: Generates high-margin promotional product revenue and gross profit.